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Abstract 
 
Background: Cell-cycle disruption is the major characteristic features of neoplastic transformation and the status of cell-cycle 
regulators can thus be utilized to assess the prognostic significance in patients with cancer. The PCNA, cyclin D1, CDK4, CDK6 
and survivin expression in the buccal mucosa was utilized to evaluate the Emodin efficacy on abnormal cell proliferation during 
7,12-dimethylbenz(a)anthracene (DMBA) induced oral carcinogenesis in golden Syrian hamsters.  
Materials and methods: Topical application of DMBA, three times a week for 14 weeks, on the hamsters' buccal pouches 
developed well differentiated squamous cell carcinoma.  
Results: Cyclin D1 and PCNA over-expression and up-regulation of CDK4, CDK6 and survivin were noticed in the buccal 
mucosa of hamsters treated with DMBA alone. Emodin administration (50mg/kg b.w) orally to hamsters treated with DMBA 
down-regulated the expression of cell proliferation markers in the buccal mucosa.   
Conclusions: The anti-cell proliferative role of Emodin is owing to its modulating efficacy on cell-cycle markers towards the 
tumor suppression during DMBA induced oral carcinogenesis. 
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Introduction 
 
Cancer, a silent killer of the human life as well as a major threat to the public health, is characterized by rapid and 
uncontrolled growth, invasion and metastasis (Kwon, 2013).  
World Health Organization in its recent report pointed out a fourteen million newly diagnosed cancer cases and 8.2 
million oral cancer related deaths by the year 2012 worldwide (Siegel et al., 2016). Oral carcinoma imposes a significant health 
burden, morbidity and mortality worldwide (Siddiqi et al., 2015). 
 While various histological types of oral cancers are recognized, squamous cell carcinoma constitutes around 90% of all 
oral carcinomas (Gondak et al., 2012). The incidence of oral carcinoma is increasing every year in several parts of the world due 
to widespread habits of tobacco and alcohol abuse (Maaly et al., 2015). 
 Worldwide, around 300,000 new oral cancer cases and 145,000 deaths due to oral carcinoma were reported in the year 
2012 (Torre et al., 2015). India reports the highest incidence of oral cancer every year, where 75,000-80,000 Indians are affected 
by this cancer every year (Hebbar et al., 2014).  
7,12-dimethylbenz(a)anthracene is commonly utilized as a major carcinogen to develop tumors in the golden Syrian 
hamsters’ buccal pouches (Karthikeyan et al., 2013).  
Buccal pouches, a pocket like anatomy, exposed to repeated topical applications of DMBA resulted in well developed 
oral squamous cell carcinoma. DMBA causes neoplasm by inducing severe inflammation and dysplasia in the buccal pouches as 
well as by causing extensive oxidative damage to DNA (Manoharan et al., 2016).  
Accumulated evidences pointed out histological, morphological, biochemical and molecular similarities between DMBA 
induced oral tumors and human oral tumors (Tanaka and Ishigamori, 2011).  
This experimental oral cancer model is therefore utilised as a preferred one to study the tumor preventive potential of 
natural products and their bioactive constituents. 
Cell-cycle disruption is the major characteristic features of neoplastic transformation and the status of cell-cycle regulators can 
thus be utilized to assess the prognostic significance in patients with cancer. Disturbance in the cell-cycle regulation is the 
hallmark of carcinogenesis (Velez et al., 2015; Bertoli et al., 2013).  
The orderly cell-cycle progression is finely monitored and regulated by cyclins, along with their regulatory enzymes, cyclin 
dependent kinases. Cyclins and cyclin dependent kinases play an essential role in the cell-cycle regulation (Lim and Kaldis, 2013). 
Several studies have pointed out cyclin D1 and cyclin dependant kinases as a significant molecular objective for the inhibition of 
oral carcinogenesis (Manoharan et al., 2015).  
PCNA, a 36k Da protein, is located on chromosome 20 and serves as a key role in the late G1→S phase of the cell-cycle. 
In eukaryotic cells, it proceeds as a cofactor of DNA polymerases (Asghar, et al., 2015).  
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PCNA is regarded as a cell proliferation marker and has a critical role in DNA repair, DNA replication and chromatin 
remodelling (Strzalka and Ziemienowicz, 2011; Diamant et al., 2012). Up-regulation of PCNA has been observed in almost all 
forms of carcinomas (Khalil et al., 2015).  
Survivin has multiple biological activities, which includes a regulatory role in mitosis and apoptosis. Survivin performs a 
key role in the immunity and cell differentiation. Survivin also plays a crucial role in invasion and angiogenesis (Chen et al., 2016; 
Jaiswal et al., 2015). Survivin has a prognostic significance, as this protein was over-expressed in several tumors, including colon, 
liver, mammary, bladder and oral carcinoma (Chen et al., 2016). 
Emodin is a purgative anthraquinone found in several plants of the genus Rhamnus especially Rhamnus frangula. It is also rich in 
Rheum emodi, a Himalayan rhubarb, Rheum palmatum, Rheum tanguticum, and Ventilago madraspatana. Emodin is also 
produced by a lot of fungi, including Aspergillus, Pyrenochaeta, and Pestalotiopsis. Emodin is commonly employed in traditional 
Chinese medicine for various diseases.  
Emodin showed protective effects against insulin resistance, hyperglycemia, obesity and endothelial cell dysfunction. Wang 
et al., (2011) explored the anticancer potential of Emodin in gallbladder cancer cells. The anti-inflammatory effect of Emodin has 
been demonstrated in Wistar rats (Chen et al., 2015). 
 Studies have also been documented the antidiabetic and hepatoprotective potential of Emodin in experimental models 
(Arvindekar et al., 2015; Bhadauria, 2010). 
 Xiong et al., (2011) demonstrated the in vitro and in vivo antiviral effect of Emodin aganist Herpes Simplex Virus. This 
study utilizes the PCNA, cyclin D1, CDK4, CDK6 and survivin expression to evaluate the effect of Emodin on abnormal cell 
proliferation occurring during DMBA induced oral carcinoma in the golden Syrian hamsters.  
 
Materials and methods 
Animals 
  
For the present study, we purchased forty male golden Syrian hamsters, weighing 80-120g, from National Institute of 
Nutrition, Hyderabad, India. The experimental hamsters were maintained at the Annamalai University Central Animal House, as 
per the Institution Ethical Committee principles (Registration Number 160/1999/ CPCSEA). The experimental hamsters were 
housed in the polypropylene animal cages and the pellet diet and water were provided ad libitum. 
 
Tumor induction 
  
Oral tumors were developed in the buccal mucosa of golden Syrian hamsters using topical application of 0.5% 7,12-dimethyl 
benz(a)anthracene in liquid paraffin (three times a week for 14 weeks).  
 
Experimental design 
  
To assess the anti-cell proliferative efficacy of Emodin, the experimental hamsters were categorized into four groups of ten 
animals in each as follows: 
 
 Group I: Topical application of  liquid paraffin alone (three times a week for 14 weeks) 
 
 Group II : Topical application of DMBA alone (0.5% in liquid paraffin, three times a week for 14 weeks) 
 
 
 Group III:Topical application of DMBA (0.5% in liquid paraffin, three times a week for 14 weeks) + Oral administration of 
Emodin (50mg/kg b.w, three times a week for  14 weeks on alternate days of DMBA application) 
 
 Group IV :   Oral administration of Emodin alone (50mg/kg b.w, three times a week for 14 weeks) 
 
Western blotting 
 After quantification of the protein in the buccal mucosa tissue extract, it was subjected to polyacrylamide gel electrophoresis 
to separate the various proteins. Then the protein bands were transferred onto PVDF membrane using electroblotting. The blots 
were then treated with corresponding primary antibodies (CDK4, CDK6 and Survivin, Cell Signaling Technology, Danvers, MA, 
USA), followed by incubation with secondary antibodies conjugated with horseradish peroxidase (Santa Cruz Biotechnology, 
USA). The obtained immune complex was then treated with the enzyme substrate, diaminobenzidine. The protein bands were 
scanned and analysed densitometrically (Bio-Rad Image Lab™ software version 4.1 software). 
 
Immunohistochemistry 
 
After a routine procedure, the buccal mucosa tissue sections were treated with the corresponding primary antibodies (PCNA and 
cyclin D1: Dako, Carprinteria, CA, USA), followed by incubation with the horseradish peroxidase labelled secondary antibodies. 
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The enzyme substrate, diaminobenzidine, was then added and the immune complex formed was viewed under the microscope, 
when acceptable color intensity was attained.  
Statistical analysis 
   
One way analysis of variance (ANOVA) followed by Duncan's Multiple Range Test (DMRT) was done to assess the 
statistical significance between the two experimental groups. The two groups were considered as statistically significant if the p 
value was less than 0.05 between them. 
 
Results 
Tumor incidence 
 
We noticed well-differentiated oral squamous cell carcinoma, confirmed by the oral pathologist, in the buccal mucosa of 
all the hamsters received topical application of DMBA alone. The tumor incidence was therefore hundred percent. While tumor 
formation was absent in the hamsters treated with DMBA+Emodin, we noticed precancerous pathological lesions such as 
hyperplasia, hyperkeratosis and dysplasia (table 1). The present results thus suggest the tumor inhibitory potential of Emodin in 
DMBA induced oral carcinogenesis. 
 
 
 
Cell proliferation markers 
  
The expression pattern of cyclin D1, PCNA (Immunohistochemistry) and CDK4, CDK6 and survivin (Western blotting) 
in the buccal mucosa of control and experimental hamsters are depicted in the figures 1, 2 and 3 respectively. Over-expression of 
cyclin D1 and PCNA and up-regulation of CDK4, CDK6 and survivin were observed in the buccal mucosa of hamsters treated 
with DMBA alone. Emodin administration at a dose of 50mg/kg b.w orally to hamsters treated with DMBA down-regulated the 
expression of the above mentioned cell proliferation markers in the buccal mucosa.   
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Table 1: Tumor incidence and histopathological features observed in control and experimental hamsters in each group. 
 
Figure 1: PCNA and Cyclin D1 expression in the buccal mucosa of experimental hamsters  
PCNA: A and D - Control and Emodin alone (expression not detectable), B - DMBA alone (over-expressed), C - DMBA + Emodin (down-regulated) 
Cyclin D1: E and H - Control and Emodin alone (expression not detectable), F - DMBA alone (over-expressed), G - DMBA + Emodin (down-regulated).
Parameter 
Liquid paraffin alone treated 
hamsters 
DMBA alone treated 
hamsters 
DMBA+ Emodin  treated 
hamsters 
Emodin alone treated 
hamsters 
Tumor incidence 0% 100% 0% 0% 
Hyperplasia Not observed Severe hyperplastic lesions  
Mild to moderate hyperplastic 
lesions 
Not observed 
Hyperkeratosis Not observed Severe hyperkeratotic lesions 
Mild to moderate 
hyperkeratotic lesions 
Not observed 
Dysplasia Not observed Severe dysplastic lesions 
Mild to moderate dysplastic 
lesions 
Not observed 
Well differentiated squamous 
cell carcinoma 
Not observed 
Tumor formation in all the 
animals 
Not observed Not observed 
Manoharan et al., Afr J Tradit Complement Altern Med. (2016) 14(2):83-91 
doi:10.21010/ajtcam.v14i2.10 
87 
 
 
Figure 2: Expression pattern of buccal mucosa CDK4, CDK6 and Survivin in the experimental hamsters.  
Lane 1: Control, Lane 2: DMBA alone, Lane 3: DMBA + Emodin, Lane 4: Emodin alone.  
 
 
Figure  3:  Densitometric analysis of protein expression after normalization to β-actin in the buccal mucosa of 
experimental hamsters  
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Data presented are the mean ± SD (n=10). Common superscripts between two groups - not significant. Different 
superscripts between two groups - significant p<0.05. 
 
 
Discussion 
 
Biomarkers play a key and critical function in determining the tumor stage as well as to plan the 
treatment options. Tumor progression occurs due to deregulation in the molecular pathways that regulate 
cellular differentiation and proliferation (Zhao and Ramaswamy, 2014). The cross talking between various 
genes either directly or indirectly could lead to tumorigenesis. A spectrum of biomarkers has been utilized to 
assess the disease status in various diseases, including cancer (Brookes and Shi, 2014). The researchers utilized 
the molecular biomarkers that has a vital function in the carcinogenic process to explore the anti-cell 
proliferative efficacy of natural products or synthetic entities (Ovadje et al., 2015). The present study explores 
the anti-cell proliferative potential of Emodin by analysing the expression pattern of cell proliferation markers in 
DMBA induced oral carcinogenesis. 
 Imbalance in cell proliferation is one of the characteristic features of carcinogenesis. Abnormal expression 
of cyclin D1 was shown in various types of malignancies, including oral carcinoma (Lee et al., 2012). Cyclin D1 
expression was associated with the tumor staging, lymphnode metastasis, grading and tumor size/thickness 
(Sarkar et al., 2015). Cyclin D1 over-expression has been correlated with the shortening of G1 phase. Though 
the cyclin D1 expression was seen in 73% of oral cancer cases, its expression was not connected with the 
survival outcome of the patients treated with preoperative chemoradiation (Basnaker, 2014). Zhang et al., (2012) 
reported that cyclin D1 status could be utilized used as a prognostic marker for tumor recurrence. Angadi and 
Krishna pillai (2007) showed a positive cyclin D1 expression in 75% of oral carcinoma cases. Zhang et al., 
(2012) showed a cyclin D1 abnormal expression in 65% of laryngeal squamous cell carcinoma patients. 
Saawarn et al., (2012) showed a direct correlation between the cyclin D1 expression and cell differentiation in 
oral cancer. Huang et al., (2012) pointed out that cyclin D1 over-expression was associated with the poor 
clinical outcome in Taiwanese oral cancer patients. Several studies have thus pointed out the cyclin D1 as a 
significant molecular target for the suppression of oral carcinogenesis. 
 Cyclin D1, CDK4 and CDK6 play a vital function in the G1 phase progression as well as in the G1→S 
transition (Pestell, 2013). Cyclin D1 triggers the gene transcription necessary for G1→S phase transition via 
binding and activating CDK4, CDK6 (Neganova and Lako, 2008). In this study, abnormal expression of cyclin 
D1, CDK4 and CDK6 was observed in the tumor tissues of all the hamsters treated with DMBA alone. Emodin 
administration orally to DMBA treated hamsters lowered the expression of cyclin D1, CDK4 and CDK6. Sui et 
al., (2014) demonstrated the inhibitory effect of Emodin on breast cancer cell proliferation. They suggested that 
Emodin inhibited breast cancer cell proliferation via down-regulation of cyclin D1 expression. Wang et al., 
(2015) suggested that Emodin exhibited antitumor potential against gynecological cancer cells via down-
regulating cyclin D and cyclin E. Zhang et al., (2015)  reported that Emodin suppressed the cell growth and 
proliferation of oral cancer cells by down-regulating the cell proliferation markers such as CDK2 and cyclin E. 
The present results indicate that Emodin might have significantly suppressed the cell proliferation of oral 
carcinoma cells in the buccal mucosa, as evidenced by down-regulation of CDK4, CDK6 and cyclin D1 in the 
DMBA+Emodin treated hamsters. 
 PCNA has been highlighted as a putative prognostic cell proliferative marker in various malignancies 
including oral carcinoma. Abnormal PCNA expression was shown in oral carcinogenesis (Al-Azzawi, 2014; 
Oliveira and Ribeiro-Silva, 2011). Survivin has a key role in the process of mitosis and cell proliferation (Xie et 
al., 2015). Survivin expression was abnormal in various cancers, including oral carcinoma (Jaiswal et al., 2015). 
A positive correlation has been reported between abnormal expression of survivin and patients with poor 
prognosis (Mobahat et al., 2014). It has been reported that survivin expression was predominant in the 
proliferating basal cell layer of the oral tumor cell mass (Xie et al., 2015). Kim et al., (2011) pointed out the 
parallel link between the survivin expression and tumor lymphnode metastasis in oral carcinogenesis. Su et al., 
(2010) suggested that survivin mRNA expression can be utilized as an independent prognostic factor for oral 
carcinoma patients. The present study observed PCNA and survivin over-expression in the buccal mucosa of 
hamsters treated with DMBA alone. Emodin administration to hamsters treated with DMBA down-regulated 
PCNA and survivin expression, which suggest that Emodin significantly inhibited the cell proliferation during 
DMBA induced oral carcinoma. The present study thus pointed out the modulatory effect of Emodin on cell 
proliferation markers during DMBA induced oral carcinogenesis. The possible mechanism of Emodin efficacy 
on abnormal cell proliferation is given in the figure 4. 
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Figure 4: The possible mechanism of Emodin efficacy on abnormal cell proliferation 
 
 
Conclusion 
  
The present research findings, explores the protective role of Emodin on abnormal cell proliferation in 
DMBA induced oral carcinoma in golden Syrian hamsters. The anti-cell proliferative potential of Emodin is 
owing to its modulating consequence on cell-cycle markers towards tumor suppression during DMBA induced 
oral carcinogenesis in golden Syrian hamsters. 
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